Cancer immunotherapy - Novel perspectives;Neue perspektiven in der immunologischen krebstherapie

Therapeutische Umschau

Volumn 69, Issue 10, 2012, Pages 559-563

  Rothschild, Sacha I ^a   Zippelius, Alfred ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; IPILIMUMAB; MONOCLONAL ANTIBODY; SIPULEUCEL T; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; EX VIVO STUDY; HUMAN; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MELANOMA; METASTASIS; NATURAL KILLER CELL; OVERALL SURVIVAL; T LYMPHOCYTE; TREATMENT RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; PROSTATE TUMOR; SKIN TUMOR; SWITZERLAND;

CANCER VACCINES; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; SWITZERLAND;

EID: 84867154990     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000330     Document Type: Article

References (29)

1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-43.
2. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-14.
3. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361: 1838-47.
4. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010; 10: 878-89.
5. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, KimSchulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010; 17: 718-30.
6. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-9.
7. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 3089-94.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-22.
9. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP et al. Vaccination with patientspecific tumor-derived antigen in first remission improves diseasefree survival in follicular lymphoma. J Clin Oncol. 2011; 29: 2787-94.
10. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364: 2119-27.
11. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol. 2010; 28: 1099-105.
12. Vansteenkiste J. Final results of a multi-center, double-blind, randomized, placebo controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007; 25 (S7554).
13. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009; 206: 1717-25.
14. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190: 355-66.
15. Ribas A, Camacho LH, LopezBerestein G, Pavlov D, Bulanhagui CA, Millham R et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23: 8968-77.
16. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008; 26: 5950-6.
17. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
18. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-26.
19. Ribas A. Phase III, open-label, randomized, comparative study of tremelimumab (CP-75,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008; 26 (LBA9011).
20. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-77.
21. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with longterm follow-up. Cancer Res. 2006; 66: 3381-5.
22. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PDL1 blockade. Proc Natl Acad Sci U S A. 2002; 99: 12293-7.
23. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005; 65: 1089-96.
24. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167-75.
25. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005; 23: 5779-87.
26. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002; 195: 1279-88.
27. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61: 6451-8.
28. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ et al. "MIATA"-minimal information about T cell assays. Immunity. 2009; 31: 527-8.
29. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011; 11: 805-12.